Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 9236

1.

Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Narváez J, López PJ, LLuch J, Narváez JA, Palmero R, Del Muro XG, Nolla JM, Domingo-Domenech E.

Autoimmun Rev. 2018 Aug 10. pii: S1568-9972(18)30185-X. doi: 10.1016/j.autrev.2018.05.002. [Epub ahead of print] Review.

PMID:
30103042
2.

MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance.

Askandar Iqbal M, Arora S, Prakasam G, Calin GA, Syed MA.

Mol Aspects Med. 2018 Aug 10. pii: S0098-2997(18)30065-7. doi: 10.1016/j.mam.2018.07.003. [Epub ahead of print] Review.

PMID:
30102929
3.

Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients.

Inada Y, Mizukoshi E, Seike T, Tamai T, Iida N, Kitahara M, Yamashita T, Arai K, Terashima T, Fushimi K, Yamashita T, Honda M, Kaneko S.

Hepatology. 2018 Aug 13. doi: 10.1002/hep.30212. [Epub ahead of print]

PMID:
30102778
4.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.

Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ.

Nat Biotechnol. 2018 Aug 13. doi: 10.1038/nbt.4195. [Epub ahead of print]

PMID:
30102295
5.

Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.

Oltolini C, Ripa M, Andolina A, Brioschi E, Cilla M, Petrella G, Gregorc V, Castiglioni B, Tassan Din C, Scarpellini P.

Mycopathologia. 2018 Aug 13. doi: 10.1007/s11046-018-0291-4. [Epub ahead of print]

PMID:
30101407
6.

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.

Wills B, Brahmer JR, Naidoo J.

Curr Treat Options Oncol. 2018 Aug 13;19(9):46. doi: 10.1007/s11864-018-0562-9. Review.

PMID:
30101402
7.

Microenvironment Cell Contribution to Lymphoma Immunity.

Kumar D, Xu ML.

Front Oncol. 2018 Jul 27;8:288. doi: 10.3389/fonc.2018.00288. eCollection 2018. Review.

8.

Targeting Resident Memory T Cells for Cancer Immunotherapy.

Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, Oudard S, Tartour E.

Front Immunol. 2018 Jul 27;9:1722. doi: 10.3389/fimmu.2018.01722. eCollection 2018. Review.

9.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Aug 9. pii: S2213-2600(18)30284-4. doi: 10.1016/S2213-2600(18)30284-4. [Epub ahead of print]

PMID:
30100403
10.

Heterogeneity of EGFR-mutant clones and PD-L1 highly-expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Aug 7. doi: 10.1093/annonc/mdy312. [Epub ahead of print] No abstract available.

PMID:
30099497
11.

Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.

Malissen N, Grob JJ.

Drugs. 2018 Aug 10. doi: 10.1007/s40265-018-0945-z. [Epub ahead of print] Review.

PMID:
30097888
12.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

13.

Immune check-point in cervical cancer.

De Felice F, Marchetti C, Palaia I, Ostuni R, Muzii L, Tombolini V, Benedetti Panici P.

Crit Rev Oncol Hematol. 2018 Sep;129:40-43. doi: 10.1016/j.critrevonc.2018.06.006. Epub 2018 Jun 18. Review.

PMID:
30097236
14.

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.

Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Gatto L, Zichi C, Ardizzoni A, Di Maio M, Massari F.

Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 19. Review.

PMID:
30097230
15.

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A.

Eur J Cancer. 2018 Aug 7;101:236-243. doi: 10.1016/j.ejca.2018.06.034. [Epub ahead of print]

PMID:
30096704
16.

Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences.

Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano RF, Ruo Redda MG, Ricardi U, Scagliotti GV, Di Maio M, Filippi AR.

Cancer Treat Rev. 2018 Jul 20;69:215-223. doi: 10.1016/j.ctrv.2018.07.010. [Epub ahead of print] Review.

PMID:
30096699
17.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2018 Aug 9;174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035. No abstract available.

PMID:
30096300
18.

Immune Checkpoint Ligand PD-L1 is Upregulated in Pulmonary Lymphangioleiomyomatosis (LAM).

Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, Wight TN, Eruslanov E, Swartz MA, Krymskaya VP.

Am J Respir Cell Mol Biol. 2018 Aug 10. doi: 10.1165/rcmb.2018-0123OC. [Epub ahead of print]

PMID:
30095976
19.

Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.

Bigras G, Mairs S, Swanson PE, Morel D, Lai R, Izevbaye I.

Appl Immunohistochem Mol Morphol. 2018 Aug 8. doi: 10.1097/PAI.0000000000000698. [Epub ahead of print]

PMID:
30095468
20.

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.

Chung V, Kos FJ, Hardwick N, Yuan Y, Chao J, Li D, Waisman J, Li M, Zurcher K, Frankel P, Diamond DJ.

Clin Transl Oncol. 2018 Aug 9. doi: 10.1007/s12094-018-1932-2. [Epub ahead of print]

PMID:
30094792

Supplemental Content

Loading ...
Support Center